Evaluation of Chronic Kidney Disease



Paul E de Jong University Medical Center Groningen The Netherlands



Evaluation and Management of CKD

- 1. Definition and classification of CKD
- 2. Definition and impact of progressive CKD
- 3. The association between CKD and CVD
- 4. The treatment of progressive CKD early, later and pre end stage interventions
- 5. Referral to specialist care



Evaluation and Management of CKD

- 1. Definition and classification of CKD
- 2. Definition and impact of progressive CKD
- 3. The association between CKD and CVD
- 4. The treatment of progressive CKD early, later and pre end stage interventions
- 5. Referral to specialist care



At present many health care systems advocate screening for CKD, especially in the elderly. Which percentage of the people with CKD is detected in 2011 (US data)?

- 1. 5% of the cases <65yr, and 12.5% of the cases >65yr
- 2. 10% of the cases <65yr, and 25% of the cases >65yr
- 3. 20% of the cases <65yr, and 50% of the cases >65yr
- 4. 30% of the cases <65yr, and 75% of the cases >65yr



In elderly with diabetes, information on the level of albuminuria is available ...

- 1. twice as often as info on the level of GFR
- 2. as frequent as info on the level of GFR
- 3. in 2 out of the 3 subjects with info on GFR
- 4. in 1 out of the 3 subjects with info on GFR



With information on the level of GFR, but without info on the level of albuminuria, the risk associated with CKD can correctly be defined in

- 1. about 2 out of the 3 cases
- 2. about half of the cases
- 3. about 20% of the cases
- 4. less than 10% of the cases



CKD: abnormalities of kidney structure or function for >3 months, with implications for health

Criteria for CKD (either of the following present for >3 months)

Markers of kidney damage	Albuminuria (AER ≥30 mg/d; ACR ≥30 mg/g [≥3 mg/mmol])
(one or more)	Urine sediment abnormalities
	Electrolyte and other abnormalities due to tubular disorders
	Abnormalities detected by histology
	Structural abnormalities detected by imaging
	History of kidney transplantation
Decreased GFR	GFR <60 ml/min/1.73 m ²
Abbreviations: CKD, chronic kidney d	isease: GER_ domenular filtration rate



Use the following albuminuria categories

Albuminuria categories in CKD					
Category	AER	ACI approximate)	R equivalent)	Terms	
	(mg/d)	(mg/mmol)	(mg/g)		
A1	<30	<3	<30	Normal to mildly increased	
A2	30-300	3-30	30-300	Moderately increased*	
A3	>300	>30	>300	Severely increased**	

Abbreviations: AER, albumin excretion rate; ACR, albumin-to-creatinine ratio; CKD, chronic kidney disease. *Relative to young adult level.

**Including nephrotic syndrome (albumin excretion usually >2200 mg/d [ACR >2220 mg/g; >220 mg/mmol]).



Use the following albuminuria categories

Albuminuria categories in CKD					
Category	AER	ACI approximate)	R equivalent)	Terms	
	(mg/d)	(mg/mmol)	(mg/g)		
A1	<30	<3	<30	Normal to mildly increased	
A2	30-300	3-30	30-300	Moderately increased*	
A3	>300	>30	>300	Severely increased**	

Abbreviations: AER, albumin excretion rate; ACR, albumin-to-creatinine ratio; CKD, chronic kidney disease. *Relative to young adult level.

**Including nephrotic syndrome (albumin excretion usually >2200 mg/d [ACR >2220 mg/g; >220 mg/mmol]).

The term "microalbuminuria" should no longer be used



Evaluation of CKD measurement of albuminuria

We suggest the following measurement for initial screening on proteinuria in a morning spot urine sample (2B)

- 1 albumin-creatinine ratio (ACR)
- 2 protein-creatinine ratio (PCR)
- 3 strip for total protein with automatic reading
- 4 strip for total protein with manual reading



Evaluation of CKD measurement of albuminuria

Confirm reagent strip positive albuminuria and proteinuria by quantitative measurement of ACR or PCR

Confirm ACR ≥30mg/g (≥3mg/mmol) in a random spot urine sample in a subsequent early morning urine sample

If a more accurate estimate is required, measure albumin or total protein excretion rate in a timed urine collection



Use the following GFR categories

	GFR categories in CKD	
GFR category	GFR (ml/min/1.73 m ²)	Terms
G1	≥90	Normal or high
G2	60-89	Mildly decreased*
G3a	45–59	Mildly to moderately decreased
G3b	30-44	Moderately to severely decreased
G4	15–29	Severely decreased
G5	<15	Kidney failure

G1 and G2 is defined CKD only in case of moderately or severely increased albuminuria



We recommend that laboratories report eGFR using the CKD-EPI creatinine equation (1B).



Levey AS et al. Ann Int Med 2009;150:604-612



Evaluation of CKD - measurement of GFR



Matsushita K et al. JAMA 2012;307:1941-51



The staging of CKD since 2002

		normoalbuminuria	micro/macroalbuminuria	
	>90		Stage 1	
GFR	60-75		Stage 2	
30-60		St	age 3	
	15-30	St	age 4	
	<15	St	age 5	

In 2002 no data on prognosis of the various stages



Risk perception in the old CKD staging system

		normoalbuminuria	micro/macroalbuminuria
	>90		Stage 1
GFR	60-75		Stage 2
	30-60	St	age 3
	15-30	St	age 4
	<15	St	age 5

Stage 3 is expected to have higher risk than stage 1 and 2



Ranking for adjusted relative risk

All-cause mortality				
	ACR <10	ACR 10–29	ACR 30–299	ACR ≥300
eGFR > 105	1.1	1.5	2.2	5.0
eGFR 90–105	Ref	1.4	1.5	3.1
eGFR 75–90	1.0	1.3	1.7	2.3
eGFR 60–75	1.0	1.4	1.8	2.7
eGFR 45–60	1.3	1.7	2.2	3.6
eGFR 30–45	1.9	2.3	3.3	4.9
eGFR 15–30	5.3	3.6	4.7	6. 6

Cardiovascular mortality

	ACR <10	ACR 10–29	ACR 30–299	ACR ≥300
eGFR > 105	0.9	1.3	2.3	2.1
eGFR 90–105	Ref	1.5	1.7	3.7
eGFR 75–90	1.0	1.3	1.6	3.7
e <mark>GFR</mark> 60–75	1.1	1.4	2.0	4.1
eGFR 45–60	1.5	2.2	2.8	4.3
eGFR 30–45	2.2	2.7	3.4	5.2
eGFR 15–30	14	7.9	4.8	8.1

Kidney failure (ESRD)

	ACR <10	ACR 10–29	ACR 30–299	ACR ≥300
eGFR > 105	Ref	Ref	7.8	18
eGFR 90–105	Ref	Ref	11	20
eGFR 75–90	Ref	Ref	3.8	48
eGFR 60–75	Ref	Ref	7.4	67
eGFR 45–60	5.2	22	40	147
eGFR 30–45	56	74	294	763
eGFR 15–30	433	1044	1056	2286

Acute kidney injury (AKI)

	ACR <10	ACR 10–29	ACR 30–299	ACR ≥300
eGFR > 105	Ref	Ref	2.7	8.4
eGFR 90–105	Ref	Ref	2.4	5.8
eGFR 75–90	Ref	Ref	2.5	4.1
eGFR 60–75	Ref	Ref	3.3	6.4
eGFR 45–60	2.2	4.9	6.4	5.9
eGFR 30–45	7.3	10	12	20
eGFR 15–30	17	17	21	29

Progressive CKD

	ACR <10	ACR 10–29	ACR 30–299	ACR ≥300
eGFR > 105	Ref	Ref	0.4	3.0
eGFR 90–105	Ref	Ref	0.9	3.3
eGFR 75–90	Ref	Ref	1.9	5.0
eGFR 60–75	Ref	Ref	3.2	8.1
eGFR 45–60	3.1	4.0	9.4	57
eGFR 30–45	3.0	19	15	22
eGFR 15–30	4.0	12	21	7.7

Meta-analysis of 45 cohorts n=1.500.000 with 5 years of follow-up

Levey AS et a; Kidney Int 2011



Staging of CKD since 2012



Levey AS et al. Kidney Int 2011;80:17-28



Better risk stratification with new CKD classification





% of US population by GFR and albuminuria classes according to 2012 classification

		normal <30 mg/g	moderate↑ 30-300 mg/g	severe ↑ ≥300 mg/g
Risk class	≥90		1.9	0.4
moderate (yellow) 7.7% (~70%)	60-89		2.2	0.3
high	45-59	3.6	0.8	0.2
(orange) 2.5% (~20%)	30-44	1.0	0.4	0.2
very high (red)	15-29	0.2	0.1	0.1
1.3% (~10%)	<15	0.0	0.0	0.1

Levey AS et al. Kidney Int 2011;80:17-28

Overall CKD prevalence 11.5%



Probability of eGFR and albuminuria testing in Medicare patients at risk for CKD



USRDS, CKD Atlas 2013

Prevalence (%) of recognized CKD is rising



	age	65+	20-64	20-64
	M	edicare	Truven Health MS	Clinformatics DataMart
2000		2.7	0.3	
2001		3.1	0.4	0.3
2002		3.4	0.5	0.4
2003		3.8	0.5	0.4
2004		4.2	0.5	0.5
2005		4.8	0.5	0.5
2006		5.9	0.6	0.6
2007		6.8	0.6	0.7
2008		7.6	0.7	0.7
2009		8.5	0.8	0.8
2010		9.2	0.8	0.9
2011		10.0	0.9	0.9

USRDS, CKD Atlas 2013



Prevalence of recognized CKD still insufficient

	65+ Medicare	20-64 Truven	20-64 Clinformatics	NHANES
2011				
20-44		0.4	0.4	6.5
45-54		0.8	1.0	8.4
55-64		1.9	2.1	15.3
65-74	6.9			29.1
75-74	12.2			49.5
85+	16.0			65.5

CKD is recognized in 10% of the cases <65yr, and in 25% of the cases >65yr (US data)

USRDS, CKD Atlas 2013



Prevalences of moderate (yellow), high (orange), and very high (red) risk





No albuminuria info: 4.8/11.5 (42%) CKD will be missed





No albuminuria info: no risk classification in GFR 30-60





No albuminuria info: only GFR ≤30 well classified





At present many health care systems advocate screening for CKD, especially in the elderly. Which percentage of the people with CKD is detected in 2011 (US data)?

- 1. 5% of the cases <65yr, and 12.5% of the cases >65yr
- 2. 10% of the cases <65yr, and 25% of the cases >65yr
- 3. 20% of the cases <65yr, and 50% of the cases >65yr
- 4. 30% of the cases <65yr, and 75% of the cases >65yr



In elderly with diabetes, information on the level of albuminuria is available ...

- 1. twice as often as info on the level of GFR
- 2. as frequent as info on the level of GFR
- 3. in 2 out of the 3 subjects with info on GFR
- 4. in 1 out of the 3 subjects with info on GFR



With information on the level of GFR, but without info on the level of albuminuria, the risk associated with CKD can correctly be defined in

- 1. about 2 out of the 3 cases
- 2. about half of the cases
- 3. about 20% of the cases
- 4. less than 10% of the cases



Evaluation and Management of CKD

- 1. Definition and classification of CKD
- 2. Definition and impact of progressive CKD
- 3. The association between CKD and CVD
- 4. The treatment of progressive CKD early, later and pre end stage interventions
- 5. Referral to specialist care



Which of the following statements on progressive CKD is <u>not</u> correct?

- A fall in GFR >-30% in 2 years is comparable to a slope in GFR >-5 ml/min/1.73m²/yr
- 2. A fall in GFR >-30% in 2 years is observed in <5% of the subjects with a baseline GFR <60 ml/min/1.73m²
- 3. A fall in GFR >-30% in 2 years is associated with an increased risk for ESRD and for mortality, independent of baseline GFR
- 4. A fall in GFR >-30% is suggested to be an alternative endpoint in clinical trials on renoprotective therapies



Definition of CKD progression

Assess GFR/albuminuria at least annually in people with CKD, and more often in people with higher risk

			Persistent albuminuria categories Description and range					
Guide to Frequency of Monitoring				A1		A2		A3
(number of times per year) by GFR and Albuminuria Category			Normal to mildly increased		Moderatel increased	y 1	Severely increased	
			<30 mg/g <3 mg/mmol		30-300 mg 3-30 mg/mn	/g nol	>300 mg/g >30 mg/mmol	
n²)	G1	Normal or high	≥90	1 if CKD		1		2
/ 1.73 n Inge	G2	Mildly de <mark>cre</mark> ased	60-89	1 if CKD		1		2
(ml/min and ra	G3a	Mildly to <mark>moderately</mark> decreased	45-59	1		2		3
gories criptior	G3b	Moderately to severely decreased	30-44	2		3		3
R cate	G4	Severely decreased	15-29	3		3		4+
GF	G5	Kidney failure	<15	4+		4+		4+

GFR and albuminuria grid to reflect the risk of progression by intensity of coloring (green, yellow, orange, red, deep red). The numbers in the boxes are a guide to the frequency of monitoring (number of times per year).

Levey AS et al. Kidney Int 2011;80:17-28



Progression of CKD



Levey AS et al. Kidney Int 2011;80:17-28



Definition of Progression of CKD

→ a decline in GFR category (per 15ml/min/1.73m²), accompanied by a 25% or more drop in GFR

or

a slope of minus 5 ml/min/1.73m²/year or more

→ it is to be studied whether progression should also be defined as a rise in albuminuria category, accompanied by a 100% or more rise in albuminuria

Risk of % change/2yr or slope of GFR for ESRD baseline eGFR <60ml/min/1.73m²





Coresh et al for the CKD-PC, submitted



Which of the following statements on progressive CKD is <u>not</u> correct?

- 1. A fall in GFR >-30% in 2 years is comparable to a slope in GFR >-5 ml/min/1.73m²/yr
- 2. A fall in GFR >-30% in 2 years is observed in <5% of the subjects with a baseline GFR <60 ml/min/1.73m²
- 3. A fall in GFR >-30% in 2 years is associated with an increased risk for ESRD and for mortality, independent of baseline GFR
- 4. A fall in GFR >-30% is suggested to be an alternative endpoint in clinical trials on renoprotective therapies



Evaluation and Management of CKD

- 1. Definition and classification of CKD
- 2. Definition and impact of progressive CKD
- 3. The association between CKD and CVD
- 4. The treatment of progressive CKD early, later and pre end stage interventions
- 5. Referral to specialist care



The association of CKD and CVD

Which of the following statements is correct?

- 1. GFR and albuminuria are independently associated with an increased risk for both ESRD and CVD
- 2. The above associations are more steep for CVD than for ESRD
- 3. The above associations depend on the presence of diabetes and/or hypertension
- 4. The above associations depend on age and ethnicity



CV/renal prognosis related to GFR and ACR



Matsushita K et al, Lancet 2010;375:2073-81 and Gansevoort RT et al Kidney Int 2011;80:93-104



KIDNEY DIS

GOBAL OUT

Hallan SI et al for the CKD-PC consortium, JAMA 2012; 308:2349-60



Adjusted HR of GFR and ACR with mortality in Asians (green), Whites (black) and Blacks (red)



Wen CP for the CKD-PC consortium, Kidney Int 2014, in press



Associations of GFR and ACR with ESRD in diabetes vs non diabetes



Fox et al.for the CKD-PC consortium. Lancet 2012;380:1662-73



Associations of GFR and ACR with ESRD in hypertensives vs non-hypertensives



Mahmoodi et al for the CKD-PC Consortium. Lancet 2012; 380: 1649-61



The association of CKD and CVD

Which of the following statements is correct?

- 1. GFR and albuminuria are independently associated with an increased risk for both ESRD and CVD
- 2. The above associations are more steep for CVD than for ESRD
- 3. The above associations depend on the presence of diabetes and/or hypertension
- 4. The above associations depend on age and ethnicity



- The new CKD classification includes 3 albuminuria classes in all GFR strata
- This classification affords better risk stratification
- However, detection of increased albuminuria thusfar stays far behind detection of impaired GFR
- Progression of CKD can be defined as a 30% loss of GFR
- CKD is associated with a worse CV and renal prognosis, in all ages, in all ethnicities, in diabetes and nondiabetes, and in hypertension and non-hypertension



Thanks for your attention

www.kdigo.org



The KDIGO grading system

Grade 1 We recommend	Patients Most people in your situation want the action,	Clinicians Most patients should receive the action, only a few not	Policy The recommendation can be used as policy or performance measure
Grade 2 We suggest	The majority of people in your situation want the action, but many not	Different choices are appropriate Decide in line with patient preferences	Debate is required before recommendation can be used as policy or performance measure

Grade Evidence

Meaning

- **A** high the true effect lies close to the estimate of the effect
- **B** moderate the true effect may be close to the estimate, but may be different
- **C** low the true effect may be substantially different from the estimate
- **D** very low the estimate of effect is very uncertain, and often far from truth